Hanchung Medical announced in June that its hyaluronic acid (HA) injectable product, Bonetta Filler, has received domestic medical device approval from Korea’s Ministry of Food and Drug Safety (MFDS).

Bonetta Filler was developed based on domestic and international literature and clinical data, with a focus on safety and biocompatibility. According to Hanchung Medical, clinical studies conducted at medical institutions in Korea and abroad demonstrated sustained volume retention and wrinkle improvement following injection.

The MFDS classified Bonetta Filler as a biomaterial medical device for tissue restoration and completed the approval process. This achievement is regarded as a meaningful milestone in the domestic aesthetic and cosmetic filler market.The Korean aesthetic filler market has been growing rapidly in recent years, driven by population aging and the widespread adoption of aesthetic medical services. Demand for hyaluronic acid fillers continues to increase, while Korean-made aesthetic medical devices are also strengthening their presence in major global markets, including Europe and the United States.

Bonetta Filler has already completed regulatory applications in Thailand and Vietnam, with product approvals expected in the first half of next year. Based on these approvals, Hanchung Medical aims to expand step-by-step into Southeast Asia and Latin American markets.

A representative from Hanchung Medical stated,
“Following this approval, we expect additional product approvals and plan to actively expand our presence in the global filler market through aggressive marketing and sales strategies to rapidly increase local market share.”